The CCS is actively recruiting cardiac care centres, cardiology clinics and cardiologists from across Canada to contribute to a pan-Canadian study about myocarditis and/or pericarditis following mRNA COVID-19 vaccination.
The CCS National Active Surveillance Study of Myocarditis and/or Pericarditis following mRNA COVID-19 Vaccination (MYCOVACC) is a multi-centre study coordinated from the University of British Columbia under the leadership of Dr. Nathaniel Hawkins. MYCOVACC is funded by the Public Health Agency of Canada.
MYCOVACC is assessing the outcomes of adult and pediatric patients with myocarditis and/or pericarditis following mRNA vaccination for up to three years. Patients will be identified through Canadian cardiac care centres, public health authorities, and the study’s research partners including COVID-VIHPR study sites.
Study participants will be assessed at three months and 12 months after diagnosis and then annually for up to three years by a participating specialist using a clinical protocol based on the CCS 2021 Clinical Practice Update. They will also be invited to complete quality of life, mental health, physical activity, and health outcome questionnaires.
Our aim is to enhance public confidence in vaccine safety so please join us in this collective action. For more information about MYCOVACC, email the study team at firstname.lastname@example.org
Other NewsSee All
June 21, 2023
With new funding, major pan-Canadian initiative broadens its scope and extends follow-up of...CCS News COVID-19 MYCOVACC
Canadian Cardiovascular Society Receives $1.6 million to Study Myocarditis and/or Pericarditis after mRNA COVID-19 Vaccination
October 27, 2022
Today, at the Canadian Cardiovascular Congress where more than 1200 cardiovascular specialists and...MYCOVACC